By 2026-05-20, Billing team must: (1) Update billing system denial rules to automatically reject claims for any laboratory tests, imaging, or treatments listed under 'Experimental, Investigational, or Unproven' section (including but not limited to: ACTH stimulation test, cytokine assays, ELISA/ACT testing, metabolomics evaluation, NK cell quantification, SPECT/PET scans, viral serologies beyond HIV, vitamin assays, acupuncture, anti-viral agents, graded exercise therapy, IVIG, rituximab, and melatonin). (2) Create denial message template referencing CPB 0369 for claims submitted for these services. (3) Instruct providers that ONLY the following exclusionary tests are medically necessary and covered: ANA, blood/serum chemistries, CBC with differential, ESR, HIV serology, liver function tests, thyroid function tests, urinalysis, and optional tests (MRI head for MS evaluation, Lyme serology if endemic, polysomnography if sleep disorder suspected, immunoglobulin levels if recurrent infections, serum cortisol, TB skin test). (4) Update encounter templates and prior auth forms to reflect covered vs. non-covered testing. (5) Add claim submission warnings in billing software for providers attempting to bill experimental tests. Failure to implement will result in claim denials and potential compliance issues with Aetna's coverage determinations.